0
0
1/6/26 at 2:05pm
Organization
FierceBiotech
Author
Nick Paul Taylor
25 words
0
Comments
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have
You are the first to view
https://www.fiercebiotech.com/biotech/alumis-beams-pivotal-data-sotyktu-rival-drive-stock-surge
Create an account
or login to join the discussion